Some people believe that Geron's reputation is tainted, its management is flawed, and took profits today. Still, Mayo's continuing successes cannot be denied, and the FDA seems to be listening to Mayo with great interest (hold modification). Mayo is in control, and the stock will move higher next week (IMHO over $4.00).
Watch GERN next week. The HOLD has been modified as Mayo Clinic continues to get remissions and possible cures for certain blood cancers (including MF). Imetelstat's (telomere control) potential in "weeding-out" cancer stem-cells is the basis for a new pipeline. A Gilead-Geron partnership makes sense.
Trend Line is Up. There is no opposition to Imetelstat as a safe and effective medicine. Hold elimination will continue. Mayo is in the driver's seat.
This is enough to keep the trend line going up for awhile, at least to $10, IMO. This is a Mayo Clinic show (then, now, and in the future). Geron will benefit, obviously, but it is Mayo's good practice of medicine, and their influence with the FDA that makes this a "slam-dunk" for investors. Mayo has a great reputation, while Geron has a storied past, with questionable management practices. The science and the medicine (Imetelstat) are 1st rate and will carry the day.
There are no additional medical reasons to inhibit the use of Imetelstat. Obviously, that will continue to be good for Geron. Large drug companies, with similar projects on their agendas, should be interested (merger, partner, etc.). Imetelstat is now in a much stronger position for some accelerated FDA approval, especially with Mayo on their side.
There is great hope. Maine sees the "light" at the end of his internal-colon tunnel. Geron is saved.
You are correct. Mayo is leading the FDA to the proper conclusions: (1) Get rid of holds, (2) Imetelstat is an important, safe, effective drug.
There is a connection and Asterias is part of that story. MF and various blood cancers (telomere control) are the immediate objectives. Beyond that, cancer stemcell elimination appears to be the holy grail in controlling and curing cancer. Apparently, Mayo and Geron have horses in that race.
I can't say that I have any sense of how these parts fit together, but they seem to have a commonality. Imetelstat and Mayo research seem to offer a very important pipeline for future medical research. This has to appeal to some large drug companies with deep pockets. Once the hold is lifted, some of these possible combinations will likely get more attention,
I own both companies. Imetelstat is real and Mayo's data is now miles high (mostly positive). There is no other drug (MF) that offers remissions and possible cures, plus a pipeline (cancer stemcells, telomeres, etc.). Seeking Alpha called this a "miracle-drug". Mayo is above reproach. My hope and pure guess is that Gilead will be smart enough to buy Geron.
It appears that the "word" has been leaked, about the future status of the so-called HOLD. The HOLD never existed for Mayo because their trials continued unimpeded, with full and complete testing at all times (read the "Irish-Reports").
Imetelstat is succeeding with remissions and potential cures at Mayo Clinic (blood cancer & beyond), in an area that is also being pursued by Gilead. These two companies have substantial common interest.
rjosmo--There may be some insider information floating around. It's hard, perhaps impossible, to keep that kind of information completely under-wraps.
The "Creep" may be a bit more. Mayo may have made its point with the FDA.
The stock price seems to be reflecting this, but only slightly for now---- "creep"
The trend line is up, as long as Mayo Clinic's results are good. I think that is cast in stone. There is OBVISOUSLY more manipulation in this stock than in most. The random-walks can be ignored, (except by short term traders). The manipulations will be less and less important, as Mayo's medical savvy, strength and skill are recognized. Mayo is not mistaken about Imetelstat, and that is a FACT.